Osteosarcoma remains one of the most aggressive primary bone cancers, particularly devastating for children, adolescents, and young adults. Despite advances in surgery and chemotherapy, patients with metastatic or relapsed disease face dismal outcomes, with five-year survival rates often dropping below 30 percent. Traditional immunotherapies that have transformed outcomes in other cancers have struggled against this solid tumour due to its complex tumour microenvironment, antigen heterogeneity, and resistance mechanisms.
What if a specific molecular pathway could be inhibited to make osteosarcoma cells dramatically more vulnerable to the powerful effects of the immune system and engineered CAR T-cells? A groundbreaking new PhD studentship at Imperial College London, funded by Sarcoma UK, offers an exceptional opportunity to explore exactly that. This fully funded doctoral position in the Department of Surgery and Cancer focuses on inhibiting the S6 kinase 2 (S6K2)/hnRNPA1 pathway to sensitise osteosarcoma to CAR T-cell therapy.
This article delves into the details of this high-impact PhD opportunity, the innovative science behind it, eligibility requirements, and why it represents a pivotal moment for aspiring researchers in cancer immunotherapy. If you hold a strong background in cell biology, molecular biology, or biochemistry and are driven to make a tangible difference in sarcoma research, this could be your pathway to a transformative career.
Scholarship Summary
- Host Country: UK
- Host University: Imperial College London
- Scholarship Type: PhD Scholarships
- Eligible Countries: All Countries
- Scholarship Benefits: Full tuition fee, Living stipend, etc.
The Persistent Challenge of Osteosarcoma and the Promise of Immunotherapy
Osteosarcoma is the most common primary malignant bone tumour, often striking during periods of rapid bone growth. Current standard treatments combine extensive surgery with multi-agent chemotherapy, yet metastatic disease—frequently spreading to the lungs—continues to challenge clinicians. Survival statistics highlight the urgent need for innovation: while localised cases achieve around 60-70% five-year survival, metastatic osteosarcoma outcomes remain poor, underscoring the limitations of conventional approaches.
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionised treatment for certain blood cancers by reprogramming a patient’s T-cells to recognise and destroy malignant cells with precision. However, translating this success to solid tumours like osteosarcoma has proven difficult. Key barriers include poor T-cell infiltration into dense tumour masses, an immunosuppressive tumour microenvironment, antigen loss or heterogeneity, and cancer cell resistance to key immune mediators such as interferon gamma (IFNγ) and tumour necrosis factor alpha (TNFα).
See More Posts in Jobs, Scholarships, Technology, Career/Motivations, Football News Feeds
Join Job Whatsapp Channel, Scholarship Whatsapp Channel, Tech Whatsapp Channel, Follow Our Twitter (X) Channel.
Recent preclinical efforts worldwide, including work enhancing chemokine homing or developing multispecific CARs targeting antigens like B7-H3, GD2, or HER2, demonstrate growing momentum. Yet, overcoming intrinsic resistance in osteosarcoma cells remains a critical hurdle. This is where the S6K2/hnRNPA1 axis enters the picture as a promising therapeutic vulnerability.
Groundbreaking Science: Inhibiting S6K2/hnRNPA1 to Sensitise Tumours
The principal investigator, Dr Olivier E Pardo, and his team at Imperial College London have discovered that targeting the RNA-binding protein hnRNPA1 or its upstream kinase S6K2 can sensitise osteosarcoma cells to IFNγ and TNFα—two cornerstone cytokines of the anticancer immune response. This inhibition appears to trigger the expression of pro-immunogenic cytokines and surface molecules on cancer cells, potentially making them far more attractive targets for immune attack and adoptive cell therapies.
The 4-year PhD project will systematically investigate this mechanism:
- First, it will map the repertoire of immune-activating factors upregulated in osteosarcoma cells upon pathway inhibition.
- Next, researchers will evaluate how this modulation enhances the efficacy of existing CAR T-cell panels in advanced 2D and 3D in vitro models, as well as patient-derived organoids that better recapitulate tumour biology.
- Finally, the most promising combination will be tested in a metastatic osteosarcoma mouse model to assess tumour clearance in a physiologically relevant setting.
This work benefits from an international collaboration with Dr Sebastien Wälchli at the University of Oslo, Norway, bringing together expertise in cancer signalling and CAR T-cell engineering. The project sits at the exciting intersection of molecular oncology, immunotherapy, and translational modelling, offering the successful candidate hands-on experience with cutting-edge techniques.
For anyone passionate about bridging basic science with clinical impact, this PhD represents a rare chance to contribute to research that could directly inform new combination therapies for a cancer with high unmet need. Learn more about the project on FindAPhD.
Scholarship Details and Funding Package
This Imperial College London PhD studentship, available for the 2026/2027 academic year, provides substantial support:
- Degree Level: Postgraduate doctoral (PhD).
- Duration: 4 years full-time.
- Funding: Covers UK (Home) tuition fees and includes a tax-free stipend of £22,780 per year. Overseas applicants are welcome but must self-fund the tuition fee difference (approximately £39,000 per year for 3.5 years).
- Number of Awards: 1.
- Mode of Study: Full time.
- Departments: Department of Surgery and Cancer.
- Application Deadline: 10 June 2026.
The studentship is open to prospective students who meet Imperial College PhD entry requirements. It is available to both Home and Overseas candidates, though funding structure differs by fee status. Note that this award is for new entrants only; current students are not eligible. Additional details, including the annual stipend confirmation, are available directly from the principal investigator.
This level of funding removes significant financial barriers, allowing focused pursuit of ambitious research goals while developing a strong academic and professional profile in one of the world’s leading institutions for medical research. Imperial College London’s Faculty of Medicine and the Department of Surgery and Cancer offer exceptional resources, collaborative networks, and access to state-of-the-art facilities.
See Also:
- Fully Funded Graduate Assistantships in Mussel Ecology at Texas A&M University USA: Drive Real Conservation Impact in Texas Freshwater Ecosystems
- Fully Funded MS and PhD Positions in Forest Ecology, Disturbance Ecology, and Fire Ecology at Utah State University USA
- Fully Funded PhD in Fisheries Ecology at Louisiana State University 2026 in USA (Stipend and Tuition Included)
Eligibility Criteria: Who Should Apply?
Ideal candidates will hold, or expect to obtain, a first or upper-second class honours degree (or equivalent) in Cell Biology, Molecular Biology, or Biochemistry. A Master’s degree in one of these fields is expected, providing a solid foundation for doctoral-level research involving complex signalling pathways, cellular assays, and in vivo models.
Strong practical experience in relevant laboratory techniques—such as cell culture, molecular cloning, protein analysis, or immunology assays—will be advantageous. Successful applicants must also satisfy Imperial College’s general PhD entry requirements, including English language proficiency for international candidates.
Diversity of thought and background is welcomed. This project suits motivated individuals with a genuine interest in cancer immunotherapy, a commitment to rigorous science, and the curiosity to tackle translational challenges. Prior exposure to cancer research, organoid models, or T-cell work would strengthen an application but is not mandatory.
For context on the supervisor’s expertise, visit Dr Olivier E Pardo’s profile at Imperial College London. His group focuses on cancer cell signalling, with a track record in drug resistance and innovative therapeutic strategies.
Step-by-Step Application Process
Applying is straightforward but competitive. Candidates should submit a CV and a covering letter—including full contact details of two referees—directly to Dr Olivier E Pardo at o.pardo@imperial.ac.uk. The covering letter should articulate your research interests, relevant experience, and motivation for this specific project.
Shortlisted applicants will progress to formal online application through Imperial College. The deadline is 10 June 2026, so early preparation is recommended. For questions, contact Dr Pardo directly (o.pardo@imperial.ac.uk or tel: 07946914196). Further information on postgraduate research in the department is available on the Imperial College website.
Application Tips for Success:
- Highlight any independent research projects or theses related to signalling pathways, RNA biology, or immunology.
- Demonstrate understanding of the project’s aims and broader implications for sarcoma patients.
- Secure strong academic references early.
- Explore Sarcoma UK’s mission and research priorities at sarcoma.org.uk to align your statement with the funder’s goals.
Click Here to See other Scholarships.
Get Standard CV and Scholarship Essay/Statement of Purpose/Motivation Letter from a Professional.
- Join this Whatsapp Channel to Get More Infos and Tips
- Join Telegram Channel for Daily Jobs, Scholarships, Business and Career Updates
Application Deadline:
10th June 2026.
Why This PhD Represents an Outstanding Opportunity
Beyond funding and topic relevance, participants will gain:
- Expertise in advanced preclinical models, including patient-derived organoids and metastatic in vivo systems.
- Exposure to international collaboration and potential for high-impact publications.
- Skills highly valued in academia, biotech, and pharmaceutical industries focused on cell therapy and oncology.
- The chance to contribute to research that could improve outcomes for osteosarcoma patients, where new options are desperately needed.
Imperial College London’s location in the heart of a vibrant scientific community, combined with strong ties to clinical partners, positions graduates for impactful careers. The project’s emphasis on universal CAR targets and pathway modulation has potential applications beyond osteosarcoma, broadening its scientific and translational scope.
Take the Next Step Toward Impactful Cancer Research
This Imperial College London PhD studentship funded by Sarcoma UK offers a compelling blend of rigorous training, innovative science, and real-world relevance. By investigating how inhibition of the S6K2/hnRNPA1 pathway can sensitise osteosarcoma to CAR T-cell therapy, the successful candidate will help address one of the most stubborn challenges in solid tumour immunotherapy.
If you are a prospective student with the required academic background and a passion for cancer biology, do not miss this deadline. Prepare your materials, reach out with thoughtful questions, and position yourself at the forefront of efforts to transform bone cancer treatment.
For more opportunities in cancer research and detailed guidance on UK PhD applications, consider resources from leading organisations and academic portals. The field urgently needs dedicated researchers ready to translate discoveries into therapies that extend and improve lives.